Results 151 to 160 of about 416,035 (333)

Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. [PDF]

, 1989
Nikolaus Romani, S Koide, Mary T. Crowley, Margit D. Witmer-Pack, Alexandra M. Livingstone, C. Garrison Fathman, Kensuke Inaba, Ralph M. Steinman   +7 more
openalex   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

(Not) Home alone: Antigen presenting cell - T Cell communication in barrier tissues. [PDF]

Front Immunol, 2022
Neuwirth T, Knapp K, Stary G.
europepmc   +1 more source

Dendritic cells with antigen-presenting capability reside in airway epithelium, lung parenchyma, and visceral pleura. [PDF]

, 1986
K Sertl, Tamiko Takemura, Erwin Tschachler, V J Ferrans, Michael Kaliner, Ethan M. Shevach   +5 more
openalex   +1 more source

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source

Artificial Antigen-Presenting Cell Topology Dictates T Cell Activation. [PDF]

ACS Nano, 2022
Wauters AC, Scheerstra JF, Vermeijlen IG, Hammink R, Schluck M, Woythe L, Wu H, Albertazzi L, Figdor CG, Tel J, Abdelmohsen LKEA, van Hest JCM.   +11 more
europepmc   +1 more source

Immune‐Mediated Encephalitis: On the Role of Antigen‐Presenting Cells in Brain Tissue [PDF]

, 1987
A. Fontana, Karl Frei, Stefan Bodmer, Erhard Hofer   +3 more
openalex   +1 more source

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

Molecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche, Renske Imschoot, Béatrice Lintermans, Lode Denolf, Joachim Taminau, Charlotte Fieuws, Geert Berx, Kris Gevaert, Kathleen B. M. Claes   +8 more
wiley   +1 more source

A general pHLA-CD80 scaffold fusion protein to promote efficient antigen-specific T cell-based immunotherapy

Molecular Therapy: Oncology
Inadequate antigen-specific T cells activation hampers immunotherapy due to complex antigen presentation. In addition, therapeutic in vivo T cell expansion is constrained by slow expansion rates and limited functionality.
Yue Wu, Xiao Liang, Yanping Sun, Jiangtao Ning, Yukun Dai, Shijie Jin, Yingchun Xu, Shuqing Chen, Liqiang Pan   +8 more
doaj  

Murine Coronavirus Disease 2019 Lethality Is Characterized by Lymphoid Depletion Associated with Suppressed Antigen-Presenting Cell Functionality. [PDF]

Am J Pathol, 2023
Lee YJ, Seok SH, Lee NY, Choi HJ, Lee YW, Chang HJ, Hwang JY, On DI, Noh HA, Lee SB, Kwon HK, Yun JW, Shin JS, Seo JY, Nam KT, Lee H, Lee HY, Park JW, Seong JK.   +18 more
europepmc   +1 more source